Evidence map›Paper›PMID 36350049›Full record

Trial reportJNCI cancer spectrum2022

Leveraging the Clinical Timepoints in Lung Cancer Screening to Engage Individuals in Tobacco Treatment.

Elyse R Park, Jordan M Neil, Elise Noonan, Sydney E Howard, Irina Gonzalez, Caylin Marotta, Amy J Wint, Douglas E Levy, Yuchiao Chang, Nancy A Rigotti and 1 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JNCI cancer spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03611881 (Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03611881 phase4completednot on this map

Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening

TypeinterventionalSponsorMassachusetts General HospitalRan2019 to 2024Enrolled642ConditionsSmoking, TobaccoArmsCounseling, Nicotine patch, Community Resource
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Updates in Lung Cancer Screening: A Decade of Evidence.Seminars in respiratory and critical care medicine · 2025
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Elyse R ParkHealth Promotion and Resiliency and Intervention Research Program, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6319-264X
Jordan M NeilHealth Promotion and Resiliency and Intervention Research Program, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Elise NoonanHealth Promotion and Resiliency and Intervention Research Program, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Sydney E HowardDivision of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Irina GonzalezHealth Promotion and Resiliency and Intervention Research Program, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Caylin MarottaDivision of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Amy J WintDivision of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Douglas E LevyMongan Institue, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Yuchiao ChangTobacco Research and Treatment Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Nancy A RigottiMongan Institue, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jennifer S HaasMongan Institue, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Harvard University · US

Funding

Research Diversity Supplement Assessing the Integration of Tobacco Cessation Treatment into Lung Cancer ScreeningR01CA218123 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HAAS, JENNIFER S, PARK, ELYSE R. · 2018 to 2022
$4.4M
NCI NIH HHS R01 CA218123
6 · The paper itself

Abstract

The US Preventive Services Task Force recommends lung cancer screening (LCS) to promote early lung cancer detection, and tobacco cessation services are strongly recommended in adjunct. Screen ASSIST (NCT03611881) is a randomized factorial trial to ascertain the best tobacco treatment intervention for smokers undergoing LCS; trial outreach is conducted during 3 recruitment points (RPs): when LCS is ordered (RP1), at screening (RP2), and following results (RP3). Among 177 enrollees enrolled from April 2019 to March 2020, 31.6% enrolled at RP1, 13.0% at RP2, and 55.4% at RP3. The average number of enrollees (per 1000 recruitment days) was 2.26 in RP1, 3.37 in RP2, and 1.04 in RP3. LCS provides an opportunity to offer tobacco treatment at multiple clinical timepoints. Repeated and proactive outreach throughout the LCS experience was beneficial to enrolling patients in tobacco cessation services.

Indexed as

Lung NeoplasmsSmoking CessationTobacco Use CessationEarly Detection of CancerHumansTobacco Products

Identifiers

PMID36350049
PMCPMC9653214
OpenAlexW4308639374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.